Seattle biotech HDT Bio is receiving $49M as part of a government project to target two deadly viruses that could affect overseas military personnel. The funding comes through a partnership with the University of Texas Medical Branch, which is leading the project. Steve Reed is the co-founder and CEO of HDT Bio.
